Last Week Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) Ratings

May 17, 2018 - By Samuel McNeil

Big Money Sentiment decreased to 1.2 in 2017 Q4. It has change of 0.53, from 2017Q3’s 1.73. The ratio fall due to Aerie Pharmaceuticals, Inc. positioning: 23 sold and 48 reduced. 21 funds amassed stakes and 64 increased stakes. Investors holded 34.42 million in 2017Q3 but now own 34.86 million shares or 1.29% more.
The New York-based Bnp Paribas Arbitrage has invested 0% in Aerie Pharmaceuticals, Inc. (NASDAQ:AERI). State Street Corporation, a Massachusetts-based fund reported 803,008 shs. Aperio Gru Limited Liability accumulated 5,721 shs or 0% of the stock. Thrivent For Lutherans holds 106,900 shs. Benchmark Advsr holds 1.38% or 29,600 shs in its capital. Pictet Asset Ltd owns 0.05% invested in Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) for 318,164 shs. Citadel Limited Liability stated it has 0% of its capital in Aerie Pharmaceuticals, Inc. (NASDAQ:AERI). State Common Retirement Fund has invested 0% in Aerie Pharmaceuticals, Inc. (NASDAQ:AERI). Principal Financial accumulated 15,406 shs or 0% of the stock. Leisure Capital invested 0.86% in Aerie Pharmaceuticals, Inc. (NASDAQ:AERI). Walleye Trading Limited Liability Company has 56 shs for 0% of their capital. Aqr Capital Mgmt Ltd Co owns 21,391 shs or 0% of their US capital. 9,966 were accumulated by Jane Street Grp Ltd. Driehaus Mgmt Limited Company reported 75,995 shs. Proshare Advsrs Ltd Limited Liability Company invested 0.01% in Aerie Pharmaceuticals, Inc. (NASDAQ:AERI).

Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) Ratings Coverage

A total of 6 analysts rate Aerie Pharma (NASDAQ:AERI) as follows: 6 “Buy”, 0 “Hold” and 0 “Sell”. Тherefore 100% are bullish. (NASDAQ:AERI) has 11 ratings reports on May 17, 2018 according to StockzIntelligence. The company rating was maintained by H.C. Wainwright on Wednesday, May 9. On Wednesday, May 9 the stock of Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) earned “Buy” rating by Mizuho. On Tuesday, May 8 the firm earned “Buy” rating by Cantor Fitzgerald. On Wednesday, February 28 the stock of Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) has “Buy” rating given by Cantor Fitzgerald. On Tuesday, January 2 the rating was maintained by Stifel Nicolaus with “Buy”. On Monday, December 18 the rating was maintained by Cantor Fitzgerald with “Buy”. On Thursday, March 29 the company was maintained by Mizuho. On Thursday, March 1 the rating was maintained by H.C. Wainwright with “Buy”. On Wednesday, January 24 the firm earned “Buy” rating by Canaccord Genuity. On Friday, February 16 the rating was reinitiated by H.C. Wainwright with “Buy”. Listed here are Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) PTs and latest ratings.

09/05/2018 Broker: H.C. Wainwright Rating: Buy New Target: $78.0000 Maintain
09/05/2018 Broker: Mizuho Rating: Buy New Target: $77.0000 Maintain
08/05/2018 Broker: Cantor Fitzgerald Rating: Buy New Target: $86.0000 Maintain
29/03/2018 Broker: Mizuho Rating: Buy New Target: $87.0000 Maintain
01/03/2018 Broker: H.C. Wainwright Rating: Buy New Target: $78.0 Maintain
28/02/2018 Broker: Cantor Fitzgerald Rating: Buy New Target: $86.0 Maintain
16/02/2018 Broker: H.C. Wainwright Old Rating: Buy New Rating: Buy New Target: $78 Reinitiate
26/01/2018 Broker: Seaport Global Rating: Buy New Target: $78 Initiates Coverage On
24/01/2018 Broker: Canaccord Genuity Rating: Buy New Target: $86.0 Maintain
02/01/2018 Broker: Stifel Nicolaus Rating: Buy New Target: $80.0 Maintain

The stock decreased 0.10% or $0.05 during the last trading session, touching $51.15.Aerie Pharmaceuticals, Inc. has volume of 226,563 shares. Since May 17, 2017 AERI has risen 16.25% and is uptrending. The stock outperformed the S&P500 by 4.70%.

Aerie Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of first-in-class therapies for the treatment of glaucoma and other eye diseases.The company has $2.02 billion market cap. The Company’s lead product candidate includes Rhopressa, a once-daily eye drop for the reduction of intraocular pressure in patients with glaucoma or ocular hypertension.Last it reported negative earnings. The firm is also developing Roclatan, a once-daily eye drop to reduce IOP that is in Phase III registration trials to treat patients with open-angle glaucoma and ocular hypertension.

For more Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) news brought out recently go to: Globenewswire.com, Benzinga.com, Businesswire.com, Benzinga.com or Gurufocus.com. The titles are as follows: “Investor Expectations to Drive Momentum within Roper Technologies, Inter Parfums, SunCoke Energy Partners, Aerie …” brought out on May 03, 2018, “Benzinga Pro’s 5 Stocks To Watch Today” on May 15, 2018, “Aerie Pharmaceuticals to Announce First Quarter 2018 Financial Results and Host Conference Call on Tuesday, May 8 …” with a publish date: April 26, 2018, “Benzinga’s Daily Biotech Pulse: Valeant Earnings, Lipocine’s FDA Watch, Invivo CFO Departure” and the last “9 Stocks Ron Baron Continues to Buy” with publication date: May 17, 2018.

Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) Analyst Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.